| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author Abstract Index
|
|
|
|
21 |
S2 |
p. S172-S189
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
21 |
S2 |
p. ii-iii
|
artikel
|
| 3 |
NP-113: Developing a national information and support group program for the carers of people living with myeloma
|
Smith, Narelle
|
|
|
21 |
S2 |
p. S170-S171
|
artikel
|
| 4 |
NP-108: Improvement in patient experience with successful implementation of a Velcade at Home program in patients with myeloma
|
Beer, Hayley
|
|
|
21 |
S2 |
p. S168-S169
|
artikel
|
| 5 |
NP-109: Improving long-term quality of life for patients living with multiple myeloma: a service evaluation
|
Henshaw, Sarah
|
|
|
21 |
S2 |
p. S169
|
artikel
|
| 6 |
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
|
Verina, Daniel
|
|
|
21 |
S2 |
p. S171
|
artikel
|
| 7 |
NP-111: Myeloma Treatment Scheduler (MyeTxScheduler): an online educational tool to help keep patients on track
|
King, Tracy
|
|
|
21 |
S2 |
p. S170
|
artikel
|
| 8 |
NP-112: Onboarding advanced practice providers to myeloma clinical teams
|
Roberts, Danielle
|
|
|
21 |
S2 |
p. S170
|
artikel
|
| 9 |
NP-110: Physical activity in multiple myeloma: a review of the literature
|
Hillengass, Michaela
|
|
|
21 |
S2 |
p. S169
|
artikel
|
| 10 |
NS-63: Adapting and improving a Myeloma Support group during the pandemic
|
Dowling, Emma
|
|
|
21 |
S2 |
p. S166-S167
|
artikel
|
| 11 |
NS-61: Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: results from the ANZ Myeloma and Related Diseases Registry
|
Moore, Elizabeth
|
|
|
21 |
S2 |
p. S165-S166
|
artikel
|
| 12 |
NS-65: Introducing frailty assessment into a myeloma service – a Quality Improvement Project (QIP)
|
Morrow, Catherine
|
|
|
21 |
S2 |
p. S167-S168
|
artikel
|
| 13 |
NS-64: Lessons learned: patient management and outcomes of Multiple Myeloma patients during the COVID-19 pandemic in New York City
|
Catamero, Donna
|
|
|
21 |
S2 |
p. S167
|
artikel
|
| 14 |
NS-66: Project to improve volume of treatment and satisfation-PIVOTS, a quality improvement project
|
Steinbach, Mary
|
|
|
21 |
S2 |
p. S168
|
artikel
|
| 15 |
NS-62: The Importance of regular disease monitoring for patients with low or low intermediate risk Monoclonal Gammopathy of Undetermined Significance (MGUS)
|
Faiman, Beth
|
|
|
21 |
S2 |
p. S166
|
artikel
|
| 16 |
OAB-018: A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma
|
Maity, Ranjan
|
|
|
21 |
S2 |
p. S12
|
artikel
|
| 17 |
OAB-056: A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM)
|
Guerrero, Camila
|
|
|
21 |
S2 |
p. S35
|
artikel
|
| 18 |
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma
|
Solli, Vincenza
|
|
|
21 |
S2 |
p. S4-S5
|
artikel
|
| 19 |
OAB-044: Anti-CD38 nanobodies as theranostic agents for multiple myeloma
|
Duray, Elodie
|
|
|
21 |
S2 |
p. S28
|
artikel
|
| 20 |
OAB-037: Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis
|
Visram, Alissa
|
|
|
21 |
S2 |
p. S24
|
artikel
|
| 21 |
OAB-017: Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells
|
Shah, Pooja
|
|
|
21 |
S2 |
p. S11
|
artikel
|
| 22 |
OAB-021: BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands
|
Xing, Lijie
|
|
|
21 |
S2 |
p. S13-S14
|
artikel
|
| 23 |
OAB-029: Bone marrow adipocytes induce metabolic reprogramming of multiple myeloma cells
|
Panaroni, Cristina
|
|
|
21 |
S2 |
p. S19
|
artikel
|
| 24 |
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)
|
Popat, Rakesh
|
|
|
21 |
S2 |
p. S2-S3
|
artikel
|
| 25 |
OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study
|
Mina, Roberto
|
|
|
21 |
S2 |
p. S3
|
artikel
|
| 26 |
OAB-031: Circular RNA protein tyrosine kinase 2 promotes cell proliferation, migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK, WNT/β-catenin signaling pathways in myeloma
|
Zhou, Fan
|
|
|
21 |
S2 |
p. S20
|
artikel
|
| 27 |
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
|
Oekelen, Oliver Van
|
|
|
21 |
S2 |
p. S38
|
artikel
|
| 28 |
OAB-040: Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström Macroglobulinemia
|
Tahri, Sabrin
|
|
|
21 |
S2 |
p. S26
|
artikel
|
| 29 |
OAB-011: Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level
|
Yan, Yuting
|
|
|
21 |
S2 |
p. S7-S8
|
artikel
|
| 30 |
OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity
|
Lind, Judith
|
|
|
21 |
S2 |
p. S19-S20
|
artikel
|
| 31 |
OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients
|
Radocha, Jakub
|
|
|
21 |
S2 |
p. S29-S30
|
artikel
|
| 32 |
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
|
Branagan, Andrew
|
|
|
21 |
S2 |
p. S29
|
artikel
|
| 33 |
OAB-019: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma
|
Gandolfi, Sara
|
|
|
21 |
S2 |
p. S12-S13
|
artikel
|
| 34 |
OAB-051: Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted treatment duration and cessation in newly diagnosed Multiple Myeloma (NDMM)
|
Costa, Luciano
|
|
|
21 |
S2 |
p. S33
|
artikel
|
| 35 |
OAB-002: Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)
|
Jakubowiak, Andrzej
|
|
|
21 |
S2 |
p. S2
|
artikel
|
| 36 |
OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial
|
Kaiser, Martin
|
|
|
21 |
S2 |
p. S8
|
artikel
|
| 37 |
OAB-039: Distinct immunoglobulin heavy-chain variable gene repertoire and its clinical relevance in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
|
Yan, Yuting
|
|
|
21 |
S2 |
p. S25
|
artikel
|
| 38 |
OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2
|
Cohen, Adam
|
|
|
21 |
S2 |
p. S15
|
artikel
|
| 39 |
OAB-041: Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease
|
Solimando, Antonio
|
|
|
21 |
S2 |
p. S26-S27
|
artikel
|
| 40 |
OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study
|
Kumar, Shaji
|
|
|
21 |
S2 |
p. S22
|
artikel
|
| 41 |
OAB-028: FAM46C-dependent tuning of endoplasmic reticulum capacity in Multiple Myeloma
|
Milan, Enrico
|
|
|
21 |
S2 |
p. S18-S19
|
artikel
|
| 42 |
OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients
|
D’Agostino, Mattia
|
|
|
21 |
S2 |
p. S34
|
artikel
|
| 43 |
OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers
|
Tiedemann, Rodger
|
|
|
21 |
S2 |
p. S7
|
artikel
|
| 44 |
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma
|
Morelli, Eugenio
|
|
|
21 |
S2 |
p. S6-S7
|
artikel
|
| 45 |
OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival
|
Muchtar, Eli
|
|
|
21 |
S2 |
p. S24-S25
|
artikel
|
| 46 |
OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis
|
Muchtar, Eli
|
|
|
21 |
S2 |
p. S23-S24
|
artikel
|
| 47 |
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
|
Lonial, Sagar
|
|
|
21 |
S2 |
p. S9
|
artikel
|
| 48 |
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
|
Jr, Larry D. Anderson,
|
|
|
21 |
S2 |
p. S17-S18
|
artikel
|
| 49 |
OAB-008: Identification of high-risk Multiple Myeloma with a plasma cell Leukemia-like transcriptomic profile
|
Bruinink, Davine Hofste op
|
|
|
21 |
S2 |
p. S6
|
artikel
|
| 50 |
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial
|
Kapoor, Prashant
|
|
|
21 |
S2 |
p. S33-S34
|
artikel
|
| 51 |
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma
|
Gulla, Annamaria
|
|
|
21 |
S2 |
p. S21
|
artikel
|
| 52 |
OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
|
Dholaria, Bhagirathbhai
|
|
|
21 |
S2 |
p. S17
|
artikel
|
| 53 |
OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study
|
Termini, Rosalinda
|
|
|
21 |
S2 |
p. S22-S23
|
artikel
|
| 54 |
OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
|
Tute, Ruth De
|
|
|
21 |
S2 |
p. S10
|
artikel
|
| 55 |
OAB-022: Monoallelic deletion of BCMA locus is a frequent feature in MM and is associated with increased genomic loss
|
Samur, Mehmet K
|
|
|
21 |
S2 |
p. S14
|
artikel
|
| 56 |
OAB-014: Newly diagnosed Multiple Myeloma patients with high levels of circulating tumor cells are distinguished by increased bone marrow plasma cell proliferation
|
Fokkema, A. Cathelijne
|
|
|
21 |
S2 |
p. S9-S10
|
artikel
|
| 57 |
OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
|
Schjesvold, Fredrik
|
|
|
21 |
S2 |
p. S32
|
artikel
|
| 58 |
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
|
Moreau, Philippe
|
|
|
21 |
S2 |
p. S1
|
artikel
|
| 59 |
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
|
Chan, Wei Yee
|
|
|
21 |
S2 |
p. S30
|
artikel
|
| 60 |
OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
|
Ghandili, Susanne
|
|
|
21 |
S2 |
p. S31-S32
|
artikel
|
| 61 |
OAB-058: Predictive relevance of sustained MRD negativity and of early loss of MRD negativity during maintenance therapy after transplant in newly diagnosed Multiple Myeloma patients
|
Belotti, Angelo
|
|
|
21 |
S2 |
p. S36-S37
|
artikel
|
| 62 |
OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma
|
Aktas-Samur, Anil
|
|
|
21 |
S2 |
p. S28
|
artikel
|
| 63 |
OAB-060: Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: results of the iTIMM trial
|
Kaiser, Martin
|
|
|
21 |
S2 |
p. S37-S38
|
artikel
|
| 64 |
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma
|
Poos, Alexandra
|
|
|
21 |
S2 |
p. S5
|
artikel
|
| 65 |
OAB-054: Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Myeloma
|
Sklavenitis-Pistofidis, Romanos
|
|
|
21 |
S2 |
p. S38-S39
|
artikel
|
| 66 |
OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
|
Oekelen, Oliver Van
|
|
|
21 |
S2 |
p. S30-S31
|
artikel
|
| 67 |
OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study
|
Donk, Niels W.C.J. van de
|
|
|
21 |
S2 |
p. S16-S17
|
artikel
|
| 68 |
OAB-042: Targeting free light chain secretion via Botulinum Neurotoxin is a novel therapeutic strategy in AL amyloidosis by inducing a terminal unfolded protein response
|
Moscvin, Maria
|
|
|
21 |
S2 |
p. S27-S28
|
artikel
|
| 69 |
OAB-032: Targeting GCK in RAS-mutant multiple myeloma offer a promising therapeutic approach
|
Li, Shirong
|
|
|
21 |
S2 |
p. S20-S21
|
artikel
|
| 70 |
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival
|
Poletti, Andrea
|
|
|
21 |
S2 |
p. S35-S36
|
artikel
|
| 71 |
OAB-020: The role of checkpoint inhibitor PD-1H/VISTA in Multiple Myeloma bone disease
|
Fu, Jing
|
|
|
21 |
S2 |
p. S13
|
artikel
|
| 72 |
OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading
|
Martello, Marina
|
|
|
21 |
S2 |
p. S37
|
artikel
|
| 73 |
OAB-016: Treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019
|
Perrot, Aurore
|
|
|
21 |
S2 |
p. S10-S11
|
artikel
|
| 74 |
OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
|
Jagannath, Sundar
|
|
|
21 |
S2 |
p. S15-S16
|
artikel
|
| 75 |
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT
|
Ocio, Enrique
|
|
|
21 |
S2 |
p. S3-S4
|
artikel
|
| 76 |
P-094: ABT-199 and epigenetic modifiers: promising novel combinations for the treatment of Multiple Myeloma
|
Flanagan, Lyndsey
|
|
|
21 |
S2 |
p. S90
|
artikel
|
| 77 |
P-128: Accompanying with additional complex karyotype is a poor prognostic factor in patients with multiple myeloma with high-risk cytogenetics in the era of novel agents
|
Uryu, Hideki
|
|
|
21 |
S2 |
p. S105
|
artikel
|
| 78 |
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice
|
McMillan, Annabel
|
|
|
21 |
S2 |
p. S59-S60
|
artikel
|
| 79 |
P-225: A first-in-human study of FOR46 in patients with triple refractory Multiple Myeloma
|
Wong, Sandy
|
|
|
21 |
S2 |
p. S164
|
artikel
|
| 80 |
P-057: A helicase “ASCC3” is coupled to FEN1-mediated genomic instability and cancer cell proliferation
|
Liao, Chengcheng
|
|
|
21 |
S2 |
p. S69-S70
|
artikel
|
| 81 |
P-035: AI-based models for the identification of critical genetic biomarkers to distinguish MM from MGUS using the WES data
|
Ruhela, Vivek
|
|
|
21 |
S2 |
p. S57
|
artikel
|
| 82 |
P-020: Altered mRNA splicing identifies novel biomarkers and therapeutic targets in AL (Amyloid light-chain) Amyloidosis
|
Chyra, Zuzana
|
|
|
21 |
S2 |
p. S50
|
artikel
|
| 83 |
P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study)
|
Zander, Thilo
|
|
|
21 |
S2 |
p. S165
|
artikel
|
| 84 |
P-213: A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma
|
Richter, Joshua
|
|
|
21 |
S2 |
p. S156-S157
|
artikel
|
| 85 |
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma
|
Moreau, Philippe
|
|
|
21 |
S2 |
p. S152-S153
|
artikel
|
| 86 |
P-010: An economic model to establish the costs associated with routes of presentation for patients with Myeloma in the UK
|
Porteous, Alex
|
|
|
21 |
S2 |
p. S44
|
artikel
|
| 87 |
P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
|
Sevindik, Omur Gokmen
|
|
|
21 |
S2 |
p. S102-S103
|
artikel
|
| 88 |
P-081: A novel circulating miRNA involved in T cell senescence of multiple myeloma patients
|
Wei, Xiaojing
|
|
|
21 |
S2 |
p. S83
|
artikel
|
| 89 |
P-215: A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
|
Rosenberg, Aaron
|
|
|
21 |
S2 |
p. S157-S158
|
artikel
|
| 90 |
P-026: A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data of 1064 Chinese patients
|
Yan, Wei
|
|
|
21 |
S2 |
p. S53
|
artikel
|
| 91 |
P-146: A prospective study of conventional skeletal survey versus Whole-body CT for osteolytic lesions in Multiple Myeloma
|
Gundesen, Michael
|
|
|
21 |
S2 |
p. S115
|
artikel
|
| 92 |
P-168: A single centre retrospective analysis on the ability to identify transplant-ineligible patients with Multiple Myeloma (MM) who are not likely to benefit from new standard therapies
|
Offidani, Massimo
|
|
|
21 |
S2 |
p. S128
|
artikel
|
| 93 |
P-074: Assessing the immune microenvironment with multiplex immunofluorescence histochemistry demonstrates proximity of cytotoxic T-cells to plasma cells in patients with newly diagnosed multiple myeloma
|
Ninkovic, Slavisa
|
|
|
21 |
S2 |
p. S79-S80
|
artikel
|
| 94 |
P-009: Assessing the predictive utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: a systematic literature review and meta-analysis
|
Kastritis, Efstathios
|
|
|
21 |
S2 |
p. S43-S44
|
artikel
|
| 95 |
P-023: Assessment of liver stiffness with shear wave elastography for hepatic AL amyloidosis
|
Miki, Hirokazu
|
|
|
21 |
S2 |
p. S52
|
artikel
|
| 96 |
P-190: A systematic literature review and indirect treatment comparison among randomized clinical trials to estimate the relative efficacy of treatments for relapsed/refractory multiple myeloma
|
Bhak, Rachel
|
|
|
21 |
S2 |
p. S141-S142
|
artikel
|
| 97 |
P-018: Automatic analysis of magnetic resonance imaging in multiple myeloma patients: deep-learning based pelvic bone marrow segmentation and radiomics analysis for prediction of plasma cell infiltration
|
Wennmann, Markus
|
|
|
21 |
S2 |
p. S49
|
artikel
|
| 98 |
P-012: Automatic bone marrow segmentation in whole-body magnetic resonance imaging: towards comprehensive, objective MRI-phenotypic bone marrow characterization in multiple myeloma
|
Wennmann, Markus
|
|
|
21 |
S2 |
p. S45-S46
|
artikel
|
| 99 |
P-046: B cell transcriptional coactivator POU2AF1 (BOB-1) modulates the protein synthesis and offers a potential vulnerability in multiple myeloma.
|
Chyra, Zuzana
|
|
|
21 |
S2 |
p. S63-S64
|
artikel
|
| 100 |
P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles
|
Mazzocchetti, Gaia
|
|
|
21 |
S2 |
p. S67
|
artikel
|
| 101 |
P-030: Bone marrow findings of Idiopathic Multicentric Castleman Disease: a histopathologic analysis and systematic literature review
|
Belyaeva, Elizaveta
|
|
|
21 |
S2 |
p. S55
|
artikel
|
| 102 |
P-077: Bone marrow microenvironment analysis of exosomal microRNAs in multiple myeloma, extramedullary disease and plasma cell leukemia
|
Gregorova, Jana
|
|
|
21 |
S2 |
p. S81
|
artikel
|
| 103 |
P-156: Bortezomib plasma concentration in multiple myeloma patients using highly sensitive LC-MS/MS method and its correlation with treatment response and peripheral neuropathy
|
Goel, Lavisha
|
|
|
21 |
S2 |
p. S121
|
artikel
|
| 104 |
P-223: Bortezomib-Thalidomide-Dexamethasone (VTD) as salvage treatment in patients with Multiple Myeloma eligible for transplantation in the real world. Long-term follow-up
|
Vasquez, Jule
|
|
|
21 |
S2 |
p. S162-S163
|
artikel
|
| 105 |
P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse
|
Agte, Sarita
|
|
|
21 |
S2 |
p. S88
|
artikel
|
| 106 |
P-143: Breakthrough – a designated pharmacist in the hemato-oncology department improves both quality and sequence of drug treatment and reduces ADR in Multiple Myeloma patients during Covid-19 pandemic
|
Alabbasi, Areen
|
|
|
21 |
S2 |
p. S113-S114
|
artikel
|
| 107 |
P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease
|
Mateos, María-Victoria
|
|
|
21 |
S2 |
p. S150-S151
|
artikel
|
| 108 |
P-158: Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion
|
Mendez, Max
|
|
|
21 |
S2 |
p. S122
|
artikel
|
| 109 |
P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma
|
Baertsch, Marc-A.
|
|
|
21 |
S2 |
p. S140-S141
|
artikel
|
| 110 |
P-040: CD138-independent strategy to predict relapse in Multiple Myeloma patients
|
Muz, Barbara
|
|
|
21 |
S2 |
p. S60
|
artikel
|
| 111 |
P-197: Central nervous system Multiple Myeloma (CNS-MM), presentation and outcomes in an Era of anti-CD38 and pomalidomide inclusive therapies
|
Khan, Maliha
|
|
|
21 |
S2 |
p. S146
|
artikel
|
| 112 |
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
|
Lonial, Sagar
|
|
|
21 |
S2 |
p. S149-S150
|
artikel
|
| 113 |
P-165: Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
|
Ruiz, Raquel García
|
|
|
21 |
S2 |
p. S126
|
artikel
|
| 114 |
P-192: Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study
|
Chen, Wenming
|
|
|
21 |
S2 |
p. S143
|
artikel
|
| 115 |
P-028: Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose and bone marrow stem cells
|
Kobari, Ladan
|
|
|
21 |
S2 |
p. S54
|
artikel
|
| 116 |
P-048: Clinical application of the weighted cytogenetic scoring system in Multiple Myeloma
|
Hwang, Yu Yan
|
|
|
21 |
S2 |
p. S64-S65
|
artikel
|
| 117 |
P-032: Clinical characteristics and outcome of 30 patients with poems syndrome in Catalonia: impact of autologous stem cell transplantation in first line and at relapse
|
Castillo-Girón, Carlos
|
|
|
21 |
S2 |
p. S55-S56
|
artikel
|
| 118 |
P-183: Clinical characteristics and outcomes in Multiple Myeloma patients younger than 40 years in a non-Caucasian population
|
Vasquez, Jule
|
|
|
21 |
S2 |
p. S137-S138
|
artikel
|
| 119 |
P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
|
Zamanillo, Irene
|
|
|
21 |
S2 |
p. S164-S165
|
artikel
|
| 120 |
P-174: Clinical study of bortezomib-based regimens of BCD, PAD and VDD for newly diagnosed multiple myeloma – an analysis of 400 cases in a single center of China
|
Deng, Shuhui
|
|
|
21 |
S2 |
p. S131-S132
|
artikel
|
| 121 |
P-047: Clonal evolution in multiple myeloma evaluated by Whole Exome Sequencing
|
Gupta, Ritu
|
|
|
21 |
S2 |
p. S64
|
artikel
|
| 122 |
P-044: Comparison of 10 Color Flowcytometry and PET/CT for prognosticating MM post-transplant: results from IMPOSE-BORTECON trial
|
Yanamandra, Uday
|
|
|
21 |
S2 |
p. S62
|
artikel
|
| 123 |
P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma
|
Chari, Ajai
|
|
|
21 |
S2 |
p. S142
|
artikel
|
| 124 |
P-182: Comparison of lenalidomide, bortezomib, dexamethasone vs bortezomib, cyclophosphamide, dexamethasone as an induction regimen in newly diagnosed myeloma patients eligible for intensive chemotherapy
|
Van de Wyngaert, Zoe
|
|
|
21 |
S2 |
p. S137
|
artikel
|
| 125 |
P-043: Comparison of MRD detection of autografts in multiple myeloma between novel high-sensitivity EuroFlow-NGF and NGS
|
Urushihara, Ryota
|
|
|
21 |
S2 |
p. S61-S62
|
artikel
|
| 126 |
P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients
|
Delforge, Michel
|
|
|
21 |
S2 |
p. S124
|
artikel
|
| 127 |
P-147: COVID-19, impact of vaccination in myeloma patients
|
Hoornaert, Ellen
|
|
|
21 |
S2 |
p. S116
|
artikel
|
| 128 |
P-154: Cytatin C: a new biomarker in Multiple Myeloma?
|
Cepeda-Piorno, Francisco Javier
|
|
|
21 |
S2 |
p. S119-S120
|
artikel
|
| 129 |
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy
|
D’Agostino, Mattia
|
|
|
21 |
S2 |
p. S74-S75
|
artikel
|
| 130 |
P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol
|
Shah, Gunjan
|
|
|
21 |
S2 |
p. S158-S159
|
artikel
|
| 131 |
P-172: Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
|
Crusoe, Edvan
|
|
|
21 |
S2 |
p. S130
|
artikel
|
| 132 |
P-180: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study
|
Sborov, Douglas
|
|
|
21 |
S2 |
p. S135-S136
|
artikel
|
| 133 |
P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies
|
Aksoy, Osman
|
|
|
21 |
S2 |
p. S83-S84
|
artikel
|
| 134 |
P-101: Detection of m-protein in acetonitrile precipitates of serum by MALDI-TOF mass spectrometry: a novel methodology
|
Mehra, Nikita
|
|
|
21 |
S2 |
p. S94
|
artikel
|
| 135 |
P-027: Development of an artificial intelligence diagnostic model based on routine laboratory results and echocardiography for the early diagnosis of light chain amyloidosis
|
Yan, Wei
|
|
|
21 |
S2 |
p. S53-S54
|
artikel
|
| 136 |
P-013: Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT
|
Kim, Juhyung
|
|
|
21 |
S2 |
p. S46
|
artikel
|
| 137 |
P-014: Disruption of chromosome territories in Multiple Myeloma
|
lima, Matheus Fabiao de
|
|
|
21 |
S2 |
p. S46-S47
|
artikel
|
| 138 |
P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
|
Richardson, Paul G.
|
|
|
21 |
S2 |
p. S156
|
artikel
|
| 139 |
P-024: Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
|
Ravichandran, Sriram
|
|
|
21 |
S2 |
p. S52
|
artikel
|
| 140 |
P-066: Effect of Daratumumab (DARA), Cyclophosphamide (C), T Halidomide (T) and Dexamethasone (D) combination of Lymphocyte populations of transplant eligible newly diagnosed Multiple Myeloma patients
|
Santos, Allan
|
|
|
21 |
S2 |
p. S75
|
artikel
|
| 141 |
P-176: Effect of induction regimen in survival in newly diagnosed multiple myeloma patients receiving consolidation with autologous stem cell transplantation
|
Garrido, David
|
|
|
21 |
S2 |
p. S132-S133
|
artikel
|
| 142 |
P-163: Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
|
Fu, Weijun
|
|
|
21 |
S2 |
p. S125
|
artikel
|
| 143 |
P-160: Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail
|
Bao, Li
|
|
|
21 |
S2 |
p. S123
|
artikel
|
| 144 |
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial
|
Dimopoulos, Meletios-Athanasios
|
|
|
21 |
S2 |
p. S143-S144
|
artikel
|
| 145 |
P-076: Evaluating the changes treatment elicit on the immune repertoire of the myeloma niche using patient-derived multiple myeloma organoid models.
|
Rodriguez, Cesar
|
|
|
21 |
S2 |
p. S80-S81
|
artikel
|
| 146 |
P-119: Evaluation of real-world frontline treatment for multiple myeloma by race
|
Kansagra, Ankit
|
|
|
21 |
S2 |
p. S99-S100
|
artikel
|
| 147 |
P-135: Evaluation of the support and knowledge provided by the chatbot (virtual conversation agent) Vik Multiple Myeloma in the management of the disease
|
Puron, Lucie
|
|
|
21 |
S2 |
p. S108-S109
|
artikel
|
| 148 |
P-221: Evolution of Dara-based regimen use along treatment lines from 2016 to 2019: a real-life study based on the French national claim database
|
Touzeau, Cyrille
|
|
|
21 |
S2 |
p. S161-S162
|
artikel
|
| 149 |
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
|
Lonial, Sagar
|
|
|
21 |
S2 |
p. S150
|
artikel
|
| 150 |
P-006: Expanded natural killer cells with daratumumab, lenalidomide and dexamethasone combination potentiates antimyeloma activity in a myeloma xenograft model
|
Lee, Je-Jung
|
|
|
21 |
S2 |
p. S42
|
artikel
|
| 151 |
P-021: Experience with autologous stem-cell transplant (auto-SCT) in patients with systemic light-chain amyloidosis (LA) at our center
|
Carbonero, Javier Díaz
|
|
|
21 |
S2 |
p. S51
|
artikel
|
| 152 |
P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial
|
Ayers, Dieter
|
|
|
21 |
S2 |
p. S139-S140
|
artikel
|
| 153 |
P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy
|
Martín, Elena Maroto
|
|
|
21 |
S2 |
p. S42-S43
|
artikel
|
| 154 |
P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma
|
Trudel, Suzanne
|
|
|
21 |
S2 |
p. S162
|
artikel
|
| 155 |
P-055: Extracellular RNA: an emerging biomarker for therapeutic monitoring in multiple myeloma
|
Mithraprabhu, Sridurga
|
|
|
21 |
S2 |
p. S68-S69
|
artikel
|
| 156 |
P-123: Extramedullary expansion of Myeloma plasma cells into CNS
|
Rihova, Lucie
|
|
|
21 |
S2 |
p. S101-S102
|
artikel
|
| 157 |
P-133: Family reported outcome measures and patient reported outcome measures in Multiple Myeloma patients
|
Midlig, Kareem
|
|
|
21 |
S2 |
p. S107-S108
|
artikel
|
| 158 |
P-011: 18F-FDG PET/MRI for imaging minimal residual disease evaluation in Multiple Myeloma
|
Barilà, Gregorio
|
|
|
21 |
S2 |
p. S45
|
artikel
|
| 159 |
P-008: First report of a patient with systemic light chain amyloidosis in the course of Multiple Myeloma treated with CAR T cells directed against B-cell maturation antigen
|
Caldés, Aina Oliver
|
|
|
21 |
S2 |
p. S43
|
artikel
|
| 160 |
P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma
|
Hillengass, Jens
|
|
|
21 |
S2 |
p. S110-S111
|
artikel
|
| 161 |
P-091: Genome-wide CRISPR/Cas9 screening identifies proteasome-related specific vulnerabilities as potential treatment options of proteasome inhibitor-resistant multiple myeloma
|
Andrej, Besse
|
|
|
21 |
S2 |
p. S88-S89
|
artikel
|
| 162 |
P-102: Genomic and systemic metabolism differences associated with racial disparities in Multiple Myeloma
|
Gallagher, Emily
|
|
|
21 |
S2 |
p. S94
|
artikel
|
| 163 |
P-068: Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset
|
Akin, Hasan Yalim
|
|
|
21 |
S2 |
p. S76
|
artikel
|
| 164 |
P-121: Healthcare resource utilization and morbidities in patients with idiopathic Multicentric Castleman Disease
|
Mukherjee, Sudipto
|
|
|
21 |
S2 |
p. S100-S101
|
artikel
|
| 165 |
P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry
|
Wagner, Lynne
|
|
|
21 |
S2 |
p. S109
|
artikel
|
| 166 |
P-064: Heterogeneity of bone marrow biopsy and bone marrow aspirate (BMA) in patients with heavily pretreated relapsed/refractory Multiple Myeloma (RRMM)
|
Boyapati, Anita
|
|
|
21 |
S2 |
p. S73-S74
|
artikel
|
| 167 |
P-067: High dimensional CyTOF analysis of the immune system of multiple myeloma patients with different responses to lenalidomide maintenance
|
Silvennoinen, Raija
|
|
|
21 |
S2 |
p. S75-S76
|
artikel
|
| 168 |
P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma
|
Ntanasis-Stathopoulos, Ioannis
|
|
|
21 |
S2 |
p. S154
|
artikel
|
| 169 |
P-056: HUWE1 orchestrates DNA Repair in response to Replicative Stress in Multiple Myeloma
|
Morgan, Jonathan
|
|
|
21 |
S2 |
p. S69
|
artikel
|
| 170 |
P-052: Identification of novel genetic loci for risk of multiple myeloma by functional annotation
|
Macauda, Angelica
|
|
|
21 |
S2 |
p. S66-S67
|
artikel
|
| 171 |
P-089: Identification of novel targets in multiple myeloma for “undruggable” RAS/CDK signaling cascade
|
Adamia, Sophia
|
|
|
21 |
S2 |
p. S87-S88
|
artikel
|
| 172 |
P-079: IL10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in Multiple Myeloma
|
Sun, Jennifer
|
|
|
21 |
S2 |
p. S82
|
artikel
|
| 173 |
P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
|
Malard, Florent
|
|
|
21 |
S2 |
p. S117
|
artikel
|
| 174 |
P-045: Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing
|
Akkus, Erman
|
|
|
21 |
S2 |
p. S63
|
artikel
|
| 175 |
P-179: Immunoparesis remains a negative prognostic factor in newly diagnosed Multiple Myeloma by competing risk analysis
|
Moreno, David
|
|
|
21 |
S2 |
p. S135
|
artikel
|
| 176 |
P-173: Impact of Daratumumab (DARA) administration during transplant-eligible newly diagnosed Multiple Myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment
|
Crusoe, Edvan
|
|
|
21 |
S2 |
p. S131
|
artikel
|
| 177 |
P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
|
Moreno, David
|
|
|
21 |
S2 |
p. S134-S135
|
artikel
|
| 178 |
P-185: Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 myeloma patients: a retrospective real-world study
|
Wang, Song-Yau
|
|
|
21 |
S2 |
p. S138-S139
|
artikel
|
| 179 |
P-036: Implementation of IgH/k Next Generation Sequencing for Multiple Myeloma Minimal Residual Disease monitoring: advantages in patients’ management during daily clinical practice.
|
Armuzzi, Silvia
|
|
|
21 |
S2 |
p. S58
|
artikel
|
| 180 |
P-031: Importance of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukemia
|
Bezdekova, Renata
|
|
|
21 |
S2 |
p. S55
|
artikel
|
| 181 |
P-003: Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15
|
Fernández, Rafael Alonso
|
|
|
21 |
S2 |
p. S40-S41
|
artikel
|
| 182 |
P-120: Improving the risk stratification of multiple myeloma with a nucleotide editor/inflammation-based scoring system
|
Shariatpanahi, Afsaneh M.
|
|
|
21 |
S2 |
p. S100
|
artikel
|
| 183 |
P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma
|
Einsele, Hermann
|
|
|
21 |
S2 |
p. S120-S121
|
artikel
|
| 184 |
P-151: Incidence of adverse events in patients with Multiple Myeloma who continued with Denosumab after receiving Denosumab or Zoledronic acid: an open-label extension study
|
Raje, Noopur
|
|
|
21 |
S2 |
p. S118
|
artikel
|
| 185 |
P-122: Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO
|
Phillips, Alexis
|
|
|
21 |
S2 |
p. S101
|
artikel
|
| 186 |
P-159: Increased risk of second primary malignancy and mortality at ten years after stem cell transplant for Multiple Myeloma: an analysis of 14,532 Patients
|
Miles, Brittany
|
|
|
21 |
S2 |
p. S122-S123
|
artikel
|
| 187 |
P-088: Indirubin-3’-monoxime acts as an alternative proteasome inhibitor and confers new regimens for the treatment of Multiple Myeloma
|
Yu, Zhen
|
|
|
21 |
S2 |
p. S87
|
artikel
|
| 188 |
P-051: Inferior outcomes for Multiple Myeloma (MM) patients (pts) harbouring t(11;14) and the promise of venetoclax, real-world Australian retrospective
|
Lim, Kenneth
|
|
|
21 |
S2 |
p. S66
|
artikel
|
| 189 |
P-069: Inflammasome-primed neutrophils maintain a pro-tumor microenvironment in Multiple Myeloma
|
de Jong, Madelon
|
|
|
21 |
S2 |
p. S76-S77
|
artikel
|
| 190 |
P-198: Isatuximab plus Carfilzomib and Dexamethasone in East Asian patients with relapsed Multiple Myeloma: IKEMA subgroup analysis
|
Kim, Kihyun
|
|
|
21 |
S2 |
p. S146-S147
|
artikel
|
| 191 |
P-196: Isatuximab plus Carfilzomib and Dexamethasone in patients with relapsed Multiple Myeloma and soft-tissue Plasmacytomas: IKEMA subgroup analysis
|
Hájek, Roman
|
|
|
21 |
S2 |
p. S145-S146
|
artikel
|
| 192 |
P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis
|
Špička, Ivan
|
|
|
21 |
S2 |
p. S159
|
artikel
|
| 193 |
P-153: Is it time for a more holistic approach to the treatment of Multiple Myeloma?
|
Sharpley, Faye
|
|
|
21 |
S2 |
p. S119
|
artikel
|
| 194 |
P-015: Is it time to revisit role of PET-CT imaging and its integration with other parameters in International Myeloma Working Group (IMWG) response assessment criteria?
|
Narang, Jayant
|
|
|
21 |
S2 |
p. S47
|
artikel
|
| 195 |
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
|
Ghobrial, Irene
|
|
|
21 |
S2 |
p. S109-S110
|
artikel
|
| 196 |
P-142: Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
|
Zhuang, Zhe
|
|
|
21 |
S2 |
p. S113
|
artikel
|
| 197 |
P-141: Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China
|
Zhuang, Zhe
|
|
|
21 |
S2 |
p. S112-S113
|
artikel
|
| 198 |
P-034: MAGNAZ trial - A prospective phase II study in patients with monoclonal gammopathy of unknown significance (MGUS) and anti-Myelin Associated Glycoprotein (MAG) Neuropathy and Zanubrutinib Treatment
|
Minnema, Monique C.
|
|
|
21 |
S2 |
p. S57
|
artikel
|
| 199 |
P-105: Mass spectrometry and artificial neural networks for discrimination of extramedullary Multiple Myeloma
|
Gregorova, Jana
|
|
|
21 |
S2 |
p. S96
|
artikel
|
| 200 |
P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma
|
Papadimitriou, Maria-Alexandra
|
|
|
21 |
S2 |
p. S71
|
artikel
|
| 201 |
P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab
|
Girgis, Suzette
|
|
|
21 |
S2 |
p. S39-S40
|
artikel
|
| 202 |
P-140: Monoclonal proteinuria ≥200 mg/24h predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
|
Visram, Alissa
|
|
|
21 |
S2 |
p. S111-S112
|
artikel
|
| 203 |
P-071: Multi-omic analysis of the tumor microenvironment reveals novel associations in a clinical trial of atezolizumab ± daratumumab for relapsed/refractory multiple myeloma
|
Cho, Hearn Jay
|
|
|
21 |
S2 |
p. S78
|
artikel
|
| 204 |
P-092: Multiple Myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
|
Chen, Tianzeng
|
|
|
21 |
S2 |
p. S89-S90
|
artikel
|
| 205 |
P-117: Multiple Myeloma treatment patterns and outcomes in the public and private healthcare systems in Brazil: one country, two worlds
|
Hungria, Vania
|
|
|
21 |
S2 |
p. S98-S99
|
artikel
|
| 206 |
P-171: Multistate models provide complementary insights into outcomes for patients treated in the UK NCRI Myeloma XI randomised trial
|
Craig, Zoe
|
|
|
21 |
S2 |
p. S129-S130
|
artikel
|
| 207 |
P-075: Myeloid derived suppressor cells are not elevated in monoclonal gammopathies
|
Rihova, Lucie
|
|
|
21 |
S2 |
p. S80
|
artikel
|
| 208 |
P-107: NCOR2 mediated MYC upregulation drives drug resistance in multiple myeloma independent of Cereblon
|
Mori, Tomoaki
|
|
|
21 |
S2 |
p. S97
|
artikel
|
| 209 |
P-095: Normal human tissue expression of G-protein coupled receptor 5D (GPRC5D), a promising novel target for Multiple Myeloma, is restricted to plasma cells and hard keratinized tissues
|
Goldsmith, Rachel
|
|
|
21 |
S2 |
p. S91
|
artikel
|
| 210 |
P-005: Novel strategy of elotuzumab and zoledronic acid with Th1-like γδT cells against myeloma
|
Harada, Takeshi
|
|
|
21 |
S2 |
p. S41-S42
|
artikel
|
| 211 |
P-208: Ongoing trials investigating in-class transition (iCT) from parenteral to oral proteasome inhibitor (PI)-based treatment with ixazomib in multiple myeloma (MM)
|
Noga, Stephen
|
|
|
21 |
S2 |
p. S153
|
artikel
|
| 212 |
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA)
|
Orlowski, Robert
|
|
|
21 |
S2 |
p. S154-S155
|
artikel
|
| 213 |
P-169: Outcome of non-transplant eligible patients with newly diagnosed multiple myeloma depending on the eligibility for clinical trials: a single institution experience
|
Tovar, Natalia
|
|
|
21 |
S2 |
p. S128-S129
|
artikel
|
| 214 |
P-175: Outcomes of autologous-allogeneic vs autologous tandem approach followed by thalidomide maintenance for transplant-eligible patients with newly diagnosed multiple myeloma: a prospective phase II-study
|
Gagelmann, Nico
|
|
|
21 |
S2 |
p. S132
|
artikel
|
| 215 |
P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma
|
Thibaud, Santiago
|
|
|
21 |
S2 |
p. S73
|
artikel
|
| 216 |
P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination
|
Terpos, Evangelos
|
|
|
21 |
S2 |
p. S104
|
artikel
|
| 217 |
P-073: PDZ proteins, SCRIB and DLG1, regulate CD86 surface expression, myeloma growth, and survival
|
Moser-Katz, Tyler
|
|
|
21 |
S2 |
p. S79
|
artikel
|
| 218 |
P-070: Peripheral blood monocyte count is a dynamic prognostic biomarker for risk stratification in Multiple Myeloma
|
Edwards, Camille
|
|
|
21 |
S2 |
p. S77
|
artikel
|
| 219 |
P-099: Perturbation of CDK7 and super-enhancer driven transcriptional programs synergistically halts multiple myeloma cell proliferation
|
Yao, Yao
|
|
|
21 |
S2 |
p. S93
|
artikel
|
| 220 |
P-004: Pharmacological inhibition and depletion strategies for SLAMF7 CAR-T cells in multiple myeloma
|
Danhof, Sophia
|
|
|
21 |
S2 |
p. S41
|
artikel
|
| 221 |
P-211: Phase 2 MARCH study: ATG-010 plus Dexamethasone in Chinese relapsed/refractory Multiple Myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI)
|
Qiu, Lugui
|
|
|
21 |
S2 |
p. S155-S156
|
artikel
|
| 222 |
P-200: Pomalidomide-based chemotherapy in plasmacytoma at relapse
|
Lee, Ji Hyun
|
|
|
21 |
S2 |
p. S148
|
artikel
|
| 223 |
P-194: Pomalidomide-based therapy in Relapsed/Refractory Multiple Myeloma: a real-world single-center experience
|
Fucci, Ludovica
|
|
|
21 |
S2 |
p. S144-S145
|
artikel
|
| 224 |
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial
|
Weisel, Katja
|
|
|
21 |
S2 |
p. S163
|
artikel
|
| 225 |
P-189: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor
|
Bahlis, Nizar J.
|
|
|
21 |
S2 |
p. S141
|
artikel
|
| 226 |
P-025: Population-based incidence and survival of AL amyloidosis in Sweden
|
Rosengren, Sara
|
|
|
21 |
S2 |
p. S52-S53
|
artikel
|
| 227 |
P-205: PORT (OP-109): Phase 2, randomised, Pharmacokinetic (PK), cross-over study of peripheral vs central intravenous administration of Melflufen in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
|
Minarik, Jiri
|
|
|
21 |
S2 |
p. S151-S152
|
artikel
|
| 228 |
P-038: Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation
|
Seval, Guldane Cengiz
|
|
|
21 |
S2 |
p. S59
|
artikel
|
| 229 |
P-097: Preclinical validation of Ecto-5’ Nucleotidase (NT5E/CD73) as a novel immunotherapeutic target in Multiple Myeloma
|
Ray, Arghya
|
|
|
21 |
S2 |
p. S92
|
artikel
|
| 230 |
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials
|
Mai, Elias
|
|
|
21 |
S2 |
p. S133-S134
|
artikel
|
| 231 |
P-103: Profiling the myeloma cell surface proteome reveals CCR10 as a potential immunotherapeutic target
|
Patino-Escobar, Bonell
|
|
|
21 |
S2 |
p. S94-S95
|
artikel
|
| 232 |
P-166: Prognostic impact of response-adjusted ISS score in Multiple Myeloma
|
Mitrovic, Marko
|
|
|
21 |
S2 |
p. S127
|
artikel
|
| 233 |
P-078: Prognostic value of immune cells in the multiple myeloma bone marrow microenvironment: a meta-analysis within silico and in vitro validation
|
Solimando, Antonio
|
|
|
21 |
S2 |
p. S81-S82
|
artikel
|
| 234 |
P-072: Progression and dissemination of experimental multiple myeloma is associated with loss of innate and adaptive immune-mediated tumor control
|
Kellermayer, Zoltán
|
|
|
21 |
S2 |
p. S78-S79
|
artikel
|
| 235 |
P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?
|
Sweeney, Nathan
|
|
|
21 |
S2 |
p. S118-S119
|
artikel
|
| 236 |
P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma
|
ODonnell, Elizabeth
|
|
|
21 |
S2 |
p. S108
|
artikel
|
| 237 |
P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma
|
O’Donnell, Elizabeth
|
|
|
21 |
S2 |
p. S117-S118
|
artikel
|
| 238 |
P-129: Quality of life reported outcomes in published research on AL Amyloidosis: a systematic literature review
|
Bristogiannis, Sotirios
|
|
|
21 |
S2 |
p. S105
|
artikel
|
| 239 |
P-086: Quantitative seroproteomics analysis of Multiple Myeloma patients treated with Tagraxofusp, a novel CD123-directed targeted therapy, identifies novel cytokine-mediated mechanism of action
|
Ray, Arghya
|
|
|
21 |
S2 |
p. S86
|
artikel
|
| 240 |
P-148: Real-life analysis of the multiple myeloma patient’s survival in a third-level hospital
|
López-Muñoz, Nieves
|
|
|
21 |
S2 |
p. S116
|
artikel
|
| 241 |
P-087: Real world efficacy and safety of venetoclax in t(11;14) multiple myeloma in Hungary
|
Szita, Virág
|
|
|
21 |
S2 |
p. S86-S87
|
artikel
|
| 242 |
P-167: Real-world elderly myeloma patients: improved survival despite more adverse risk factors than younger patients and RCT populations. A study on behalf of the Nordic Myeloma Study Group
|
Moore, Kari Lenita Falck
|
|
|
21 |
S2 |
p. S127-S128
|
artikel
|
| 243 |
P-002: Real-world observations and practical considerations of subcutaneous daratumumab administration in multiple myeloma
|
Kim, E. Bridget
|
|
|
21 |
S2 |
p. S40
|
artikel
|
| 244 |
P-199: Real-world toxicity and efficacy of ixazomib, lenalidomide and dexamethasone in Asian RRMM patients supported by the patient assistance program
|
Lee, Ji Hyun
|
|
|
21 |
S2 |
p. S147-S148
|
artikel
|
| 245 |
P-019: Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study
|
Jimenez-Zepeda, Victor H
|
|
|
21 |
S2 |
p. S49-S50
|
artikel
|
| 246 |
P-184: Regional differences in treatment and outcome for myeloma patients in Sweden: a population based Swedish Myeloma Register study
|
Wålinder, Göran
|
|
|
21 |
S2 |
p. S138
|
artikel
|
| 247 |
P-083: Rejuvenated BCMA-specific CD8+ Cytotoxic T lymphocytes derived from induced pluripotent stem cells for treatment of Multiple Myeloma
|
Bae, Jooeun
|
|
|
21 |
S2 |
p. S84
|
artikel
|
| 248 |
P-118: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma
|
Jung, Sung-Hoon
|
|
|
21 |
S2 |
p. S99
|
artikel
|
| 249 |
P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin
|
Terpos, Evangelos
|
|
|
21 |
S2 |
p. S160
|
artikel
|
| 250 |
P-115: Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
|
Garcia-Guiñón, Antonio
|
|
|
21 |
S2 |
p. S97-S98
|
artikel
|
| 251 |
P-017: Repeatability and reproducibility of apparent diffusion coefficient measurements of bone marrow in magnetic resonance imaging of multiple myeloma patients
|
Wennmann, Markus
|
|
|
21 |
S2 |
p. S48-S49
|
artikel
|
| 252 |
P-144: Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy
|
Bird, Sarah
|
|
|
21 |
S2 |
p. S114
|
artikel
|
| 253 |
P-164: Safety of lenalidomide (LEN)-based therapy vs non–LEN-based therapy for transplant-ineligible newly diagnosed multiple myeloma (TNE NDMM): update from the post-authorization study MM-034
|
Gamberi, Barbara
|
|
|
21 |
S2 |
p. S125-S126
|
artikel
|
| 254 |
P-195: Salvage autologous stem cells transplantation and maintenance therapy in relapsed refractory multiple myeloma
|
Garrido, David
|
|
|
21 |
S2 |
p. S145
|
artikel
|
| 255 |
P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma
|
Moreau, Philippe
|
|
|
21 |
S2 |
p. S152
|
artikel
|
| 256 |
P-214: Sequencing of treatment regimens after lenalidomide (LEN) in patients with multiple myeloma (MM) in a US community oncology setting
|
Rifkin, Robert
|
|
|
21 |
S2 |
p. S157
|
artikel
|
| 257 |
P-037: Serum-free light chain and heavy-light chains normalization as markers for negative measurable residual disease in Multiple Myeloma after autologous stem cell transplant
|
Bergantim, Rui
|
|
|
21 |
S2 |
p. S58-S59
|
artikel
|
| 258 |
P-100: Serum protein electrophoresis screening as a part of health-check program in Korea
|
Lee, Sun Min
|
|
|
21 |
S2 |
p. S93
|
artikel
|
| 259 |
P-033: Significant markers in the progression of monoclonal gammopathy of undetermined significance in residents of Gomel region of Belarus
|
Kozich, Zhanna
|
|
|
21 |
S2 |
p. S56
|
artikel
|
| 260 |
P-080: Single-cell transcriptomic analysis of bone marrow NK cells reveals loss of activated cytotoxic NK cells in Multiple Myeloma
|
Tahri, Sabrin
|
|
|
21 |
S2 |
p. S82-S83
|
artikel
|
| 261 |
P-061: Single-cell whole-exome DNA sequencing traces clonal trajectory in paired evolution of MGUS to multiple myeloma
|
Ansari-Pour, Naser
|
|
|
21 |
S2 |
p. S72
|
artikel
|
| 262 |
P-029: 1st line combination treatment with proteasome-inhibitor and zoledronic acid is effective in reducing later fractures in multiple myeloma irrespective of MM bone disease
|
Nivakoski, Elise
|
|
|
21 |
S2 |
p. S54
|
artikel
|
| 263 |
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics
|
Rippe, Karsten
|
|
|
21 |
S2 |
p. S71-S72
|
artikel
|
| 264 |
P-098: Super-enhancer-driven PPP1R15B as an oncogenic and potential therapeutic target in Multiple Myeloma
|
Xiong, Sinan
|
|
|
21 |
S2 |
p. S92-S93
|
artikel
|
| 265 |
P-022: Survival benefit observed with Birtamimab in Mayo Stage IV AL amyloidosis supports initiation of confirmatory AFFIRM-AL phase 3 study
|
Gertz, Morie
|
|
|
21 |
S2 |
p. S51
|
artikel
|
| 266 |
P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets
|
Shah, Urvi
|
|
|
21 |
S2 |
p. S61
|
artikel
|
| 267 |
P-096: Tackling pyrimidine biosynthesis - CTP Synthase 1 is a novel target in the treatment of multiple myeloma
|
Pfeiffer, Christina
|
|
|
21 |
S2 |
p. S91-S92
|
artikel
|
| 268 |
P-218: Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry
|
Tedjaseputra, Aditya
|
|
|
21 |
S2 |
p. S159-S160
|
artikel
|
| 269 |
P-106: Targeting DNA2 overcomes myeloma cells’ metabolic reprogramming in response to DNA damage
|
Thongon, Natthakan
|
|
|
21 |
S2 |
p. S96-S97
|
artikel
|
| 270 |
P-104: Targeting the mitochondrial protease CLPP in Multiple Myeloma
|
Perini, Tommaso
|
|
|
21 |
S2 |
p. S95
|
artikel
|
| 271 |
P-058: The dynamics of nucleotide variants in the progression from myeloma precursor conditions to multiple myeloma using targeted sequencing of serial bone marrow samples
|
Oben, Bénedith
|
|
|
21 |
S2 |
p. S70
|
artikel
|
| 272 |
P-145: The effect of a 6-week Nordic walking training cycle on myeloma-related blood parameters, vitamin 25(OH)D3 serum concentration and peripheral polyneuropathy symptoms in patients with multiple myeloma
|
Czerwińska-Ledwig, Olga
|
|
|
21 |
S2 |
p. S114-S115
|
artikel
|
| 273 |
P-124: The history of survival improvement in patients with Multiple Myeloma through real-world data in a 45-year period at a single institution
|
Rodríguez-Lobato, Luis Gerardo
|
|
|
21 |
S2 |
p. S102
|
artikel
|
| 274 |
P-062: The impact of Bortezomib-based induction on chromosome 1q21 gained newly diagnosed Multiple Myeloma of Chinese origin
|
Tang, Hoi Ki Karen
|
|
|
21 |
S2 |
p. S72-S73
|
artikel
|
| 275 |
P-139: The impact of CD56 expression in smoldering Multiple Myeloma
|
Notarfranchi, Laura
|
|
|
21 |
S2 |
p. S111
|
artikel
|
| 276 |
P-130: The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patients
|
Joyner, Katie
|
|
|
21 |
S2 |
p. S106
|
artikel
|
| 277 |
P-116: The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
|
Ho, P. Joy
|
|
|
21 |
S2 |
p. S98
|
artikel
|
| 278 |
P-126: The prognostic impact of the UK Myeloma Research Alliance Risk Profile in untreated patients with multiple myeloma who received melphalan, prednisolone, and bortezomib: an ad hoc analysis of JCOG1105
|
Suzuki, Tomotaka
|
|
|
21 |
S2 |
p. S103-S104
|
artikel
|
| 279 |
P-016: The role [18F]-(2S,4R)-4-Fluoroglutamine as a new positron emission tomography tracer in Myeloma in vivo models.
|
Toscani, Denise
|
|
|
21 |
S2 |
p. S47-S48
|
artikel
|
| 280 |
P-041: The role of Lenalidomide maintenance and measurable residual disease in a real-life multiple myeloma transplanted population receiving different strategies guided by accessible treatments in Brazil
|
Salgado, Anna Beatriz
|
|
|
21 |
S2 |
p. S60-S61
|
artikel
|
| 281 |
P-157: The safety and efficacy of Apixaban in patients with Multiple Myeloma on immunomodulatory therapy: real-world, single centre experience
|
Hartley, Sarah
|
|
|
21 |
S2 |
p. S121-S122
|
artikel
|
| 282 |
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing
|
John, Lukas
|
|
|
21 |
S2 |
p. S65
|
artikel
|
| 283 |
P-186: Toxicity and survival outcomes of autologous stem cell transplant in Multiple Myeloma patients with renal impairment
|
Wang, Samuel
|
|
|
21 |
S2 |
p. S139
|
artikel
|
| 284 |
P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants
|
Andrews, Joel
|
|
|
21 |
S2 |
p. S129
|
artikel
|
| 285 |
P-181: Treatment outcome and prognostic factors of newly diagnosed Multiple Myeloma receiving Bortezomib-based induction in Hong Kong: an analysis of 448 patients
|
Tang, Hoi Ki Karen
|
|
|
21 |
S2 |
p. S136-S137
|
artikel
|
| 286 |
P-132: Trial in progress: a mixed methods approach to understanding treatment experience of individuals receiving standard of care Isatuximab using patient reported, wearable, and digital health outcomes
|
Manasanch, Elisabet
|
|
|
21 |
S2 |
p. S107
|
artikel
|
| 287 |
P-054: TRIM33 loss in Multiple Myeloma is associated with defective DNA repair and sensitivity to PARP inhibition
|
McAvera, Roisin
|
|
|
21 |
S2 |
p. S68
|
artikel
|
| 288 |
P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma
|
Malek, Ehsan
|
|
|
21 |
S2 |
p. S148-S149
|
artikel
|
| 289 |
P-093: Ubiquitin receptor PSMD4/Rpn10 as therapeutic target in Multiple Myeloma
|
Du, Ting
|
|
|
21 |
S2 |
p. S90
|
artikel
|
| 290 |
P-161: Ultra-high-risk prognostic significance of double and triple hit myeloma
|
Bila, Jelena
|
|
|
21 |
S2 |
p. S123-S124
|
artikel
|
| 291 |
P-085: Updated outcomes on Lenalidomide (Len) refractory MM patients’
|
Gkioka, Annita Ioanna
|
|
|
21 |
S2 |
p. S85-S86
|
artikel
|
| 292 |
P-220: Use of Carfilzomib regimens in patients with Multiple Myeloma refractory to CD38 antibodies: a subgroup analysis from a prospective observational study
|
Terpos, Evangelos
|
|
|
21 |
S2 |
p. S160-S161
|
artikel
|
| 293 |
P-131: Use of the European Organisation for research and treatment of cancer quality of life Multiple Myeloma questionnaire (EORTC QLQ-MY20): a review of the literature 25 years after development
|
Tinsley, Katie
|
|
|
21 |
S2 |
p. S106-S107
|
artikel
|
| 294 |
P-084: Venetoclax monotherapy is feasible and efficient in patients with bcl-2 overexpressing relapsed/refractory multiple myeloma at high-risk sites: a case series
|
dos Santos, David Cordas
|
|
|
21 |
S2 |
p. S85
|
artikel
|
| 295 |
P-050: Whole Exome Sequencing provides novel insights in synonymous and non-synonymous mutational landscapes of Multiple Myeloma
|
Kaur, Gurvinder
|
|
|
21 |
S2 |
p. S65-S66
|
artikel
|
Tijdschrift beschrijving